TheBodyPro clinical review
Modern antiretroviral therapy (ART) regimens have reshaped clinical outcomes and quality of life for people living with HIV. But for individuals who are highly treatment-experienced, resistance and tolerability issues may limit treatment options.
A significant proportion of people who have taken several HIV treatment regimens exhibit resistance to at least one ART agent, with some studies identifying two-class resistance in nearly 60% of participants and three-class resistance in up to 6% of participants. In addition to transmitted or acquired drug resistance, inconsistent access and suboptimal adherence to ART constitute significant challenges that increase the risk of virologic failure for individuals with a long history of treatment.
Long-acting ART options have equipped providers with new tools for addressing the unmet needs and preferences of a broad spectrum of patients. Novel ART classes with improved tolerability and no cross-resistance to other agents may help optimize regimens for individuals with resistance to multiple drug classes.
Read the full review here.
Source : TheBodyPro
Related HIV and Co-Infections News
-
[Press release] TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 in HIV maintenance therapy study
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.